Balice-Gordon Rita J. 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
COLLEGIUM PHARMACEUTICAL (COLL) Director Rita Balice-Gordon Receives Award
What Happened
Rita J. Balice-Gordon, a director of Collegium Pharmaceutical, was granted 8,741 restricted stock units (RSUs) on 2026-05-14. The award is reported at $0.00 (no cash paid). Each RSU represents a contingent right to receive one share of Collegium common stock; the RSUs will convert into shares when they vest.
Key Details
- Transaction date: 2026-05-14; Form 4 filed 2026-05-18 (timely filing).
- Grant: 8,741 RSUs @ $0.00 (award/grant code A). Reported dollar value: $0.
- Vesting/settlement: RSUs vest on the earlier of May 14, 2027 or the 2027 Annual Meeting of Shareholders, subject to continued service. Settlement will be in shares on vesting or earlier upon the director’s election, end of service, death/disability, or a change in control (per footnote).
- Shares owned after transaction: Not disclosed in this filing.
- Exhibit noted: 24.1 — Power of Attorney.
Context
This is an equity compensation grant to a board director (not an open-market purchase or sale). RSU grants are common for aligning directors with shareholder interests but do not represent an immediate cash investment or market sentiment by the insider. Watch future Form 4 filings for settlement (when shares are actually delivered) or for any sales that follow vesting.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-14+8,741→ 61,370 total
Footnotes (1)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.